CN113151135A - Food safety-grade bacillus subtilis and application thereof in production of chitobiose deacetylase - Google Patents
Food safety-grade bacillus subtilis and application thereof in production of chitobiose deacetylase Download PDFInfo
- Publication number
- CN113151135A CN113151135A CN202110536143.4A CN202110536143A CN113151135A CN 113151135 A CN113151135 A CN 113151135A CN 202110536143 A CN202110536143 A CN 202110536143A CN 113151135 A CN113151135 A CN 113151135A
- Authority
- CN
- China
- Prior art keywords
- bacillus subtilis
- dac
- nprb
- recombinant
- chitobiose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 244000063299 Bacillus subtilis Species 0.000 title claims abstract description 88
- 235000014469 Bacillus subtilis Nutrition 0.000 title claims abstract description 88
- 101710086811 Chitooligosaccharide deacetylase Proteins 0.000 title claims abstract description 55
- 235000013305 food Nutrition 0.000 title abstract description 7
- 238000004519 manufacturing process Methods 0.000 title description 7
- 108010076504 Protein Sorting Signals Proteins 0.000 claims abstract description 51
- 238000000034 method Methods 0.000 claims abstract description 31
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 56
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 56
- 229960002442 glucosamine Drugs 0.000 claims description 39
- 238000000855 fermentation Methods 0.000 claims description 37
- 230000004151 fermentation Effects 0.000 claims description 37
- 239000013598 vector Substances 0.000 claims description 28
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 15
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims description 15
- 101150077915 oppA gene Proteins 0.000 claims description 13
- 239000000758 substrate Substances 0.000 claims description 13
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims description 12
- 229950006780 n-acetylglucosamine Drugs 0.000 claims description 12
- 239000013612 plasmid Substances 0.000 claims description 11
- 206010010071 Coma Diseases 0.000 claims description 10
- 238000012258 culturing Methods 0.000 claims description 10
- 241000276408 Bacillus subtilis subsp. subtilis str. 168 Species 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 108020004414 DNA Proteins 0.000 claims description 7
- 101710089384 Extracellular protease Proteins 0.000 claims description 7
- 239000000047 product Substances 0.000 claims description 6
- 239000003054 catalyst Substances 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 101150009126 C4 gene Proteins 0.000 claims description 2
- 108091026898 Leader sequence (mRNA) Proteins 0.000 claims description 2
- 108700009124 Transcription Initiation Site Proteins 0.000 claims description 2
- 235000015872 dietary supplement Nutrition 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 230000004927 fusion Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000002054 inoculum Substances 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 abstract description 48
- 108090000790 Enzymes Proteins 0.000 abstract description 48
- 230000000694 effects Effects 0.000 abstract description 39
- 238000006243 chemical reaction Methods 0.000 abstract description 10
- 238000012986 modification Methods 0.000 abstract description 7
- 230000004048 modification Effects 0.000 abstract description 7
- 230000028327 secretion Effects 0.000 abstract description 7
- 239000013604 expression vector Substances 0.000 abstract description 4
- 230000002349 favourable effect Effects 0.000 abstract description 4
- 238000010353 genetic engineering Methods 0.000 abstract description 2
- 238000001308 synthesis method Methods 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 26
- FZHXIRIBWMQPQF-UHFFFAOYSA-N Glc-NH2 Natural products O=CC(N)C(O)C(O)C(O)CO FZHXIRIBWMQPQF-UHFFFAOYSA-N 0.000 description 17
- 241000894006 Bacteria Species 0.000 description 14
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 12
- 239000004472 Lysine Substances 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 238000010276 construction Methods 0.000 description 11
- 238000001514 detection method Methods 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 150000001413 amino acids Chemical group 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 9
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 238000012795 verification Methods 0.000 description 8
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 7
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 6
- 229960001911 glucosamine hydrochloride Drugs 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 229930027917 kanamycin Natural products 0.000 description 5
- 229960000318 kanamycin Drugs 0.000 description 5
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 5
- 229930182823 kanamycin A Natural products 0.000 description 5
- 229930182817 methionine Natural products 0.000 description 5
- 230000008439 repair process Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 4
- 101100544639 Bacillus subtilis (strain 168) yncM gene Proteins 0.000 description 4
- 101100544635 Escherichia coli (strain K12) yncI gene Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- 239000001888 Peptone Substances 0.000 description 4
- 108010080698 Peptones Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 4
- 229960001230 asparagine Drugs 0.000 description 4
- 235000009582 asparagine Nutrition 0.000 description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 229960005091 chloramphenicol Drugs 0.000 description 4
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 235000019319 peptone Nutrition 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000010443 CRISPR/Cpf1 gene editing Methods 0.000 description 3
- 229920001661 Chitosan Polymers 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- 239000012880 LB liquid culture medium Substances 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- DUKURNFHYQXCJG-UHFFFAOYSA-N Lewis A pentasaccharide Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(C)=O)C(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)OC1CO DUKURNFHYQXCJG-UHFFFAOYSA-N 0.000 description 3
- 206010073261 Ovarian theca cell tumour Diseases 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000036983 biotransformation Effects 0.000 description 3
- 229910000397 disodium phosphate Inorganic materials 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 238000009630 liquid culture Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 208000001644 thecoma Diseases 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 239000002028 Biomass Substances 0.000 description 2
- 108091033409 CRISPR Proteins 0.000 description 2
- 238000010354 CRISPR gene editing Methods 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 2
- 239000007836 KH2PO4 Substances 0.000 description 2
- FZHXIRIBWMQPQF-VANKVMQKSA-N L-glucosamine Chemical compound O=C[C@@H](N)[C@H](O)[C@@H](O)[C@@H](O)CO FZHXIRIBWMQPQF-VANKVMQKSA-N 0.000 description 2
- 108020004485 Nonsense Codon Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- QLTSDROPCWIKKY-PMCTYKHCSA-N beta-D-glucosaminyl-(1->4)-beta-D-glucosamine Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O)[C@@H](CO)O1 QLTSDROPCWIKKY-PMCTYKHCSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000010362 genome editing Methods 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 230000037434 nonsense mutation Effects 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000011218 seed culture Methods 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- NOIIUHRQUVNIDD-UHFFFAOYSA-N 3-[[oxo(pyridin-4-yl)methyl]hydrazo]-N-(phenylmethyl)propanamide Chemical compound C=1C=CC=CC=1CNC(=O)CCNNC(=O)C1=CC=NC=C1 NOIIUHRQUVNIDD-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 208000035404 Autolysis Diseases 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- YIFUFYZELCMPJP-YUMQZZPRSA-N Gly-Leu-Cys Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(O)=O YIFUFYZELCMPJP-YUMQZZPRSA-N 0.000 description 1
- 108020005004 Guide RNA Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WNGVUZWBXZKQES-YUMQZZPRSA-N Leu-Ala-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O WNGVUZWBXZKQES-YUMQZZPRSA-N 0.000 description 1
- BPANDPNDMJHFEV-CIUDSAMLSA-N Leu-Asp-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O BPANDPNDMJHFEV-CIUDSAMLSA-N 0.000 description 1
- FOEHRHOBWFQSNW-KATARQTJSA-N Leu-Cys-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)N)O FOEHRHOBWFQSNW-KATARQTJSA-N 0.000 description 1
- KPYAOIVPJKPIOU-KKUMJFAQSA-N Leu-Lys-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O KPYAOIVPJKPIOU-KKUMJFAQSA-N 0.000 description 1
- DAYQSYGBCUKVKT-VOAKCMCISA-N Leu-Thr-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O DAYQSYGBCUKVKT-VOAKCMCISA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- SJNZALDHDUYDBU-IHRRRGAJSA-N Lys-Arg-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(O)=O SJNZALDHDUYDBU-IHRRRGAJSA-N 0.000 description 1
- BLIPQDLSCFGUFA-GUBZILKMSA-N Met-Arg-Asn Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O BLIPQDLSCFGUFA-GUBZILKMSA-N 0.000 description 1
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000522615 Pyrococcus horikoshii Species 0.000 description 1
- 241000589499 Thermus thermophilus Species 0.000 description 1
- DOBIBIXIHJKVJF-XKBZYTNZSA-N Thr-Ser-Gln Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(N)=O DOBIBIXIHJKVJF-XKBZYTNZSA-N 0.000 description 1
- AHERARIZBPOMNU-KATARQTJSA-N Thr-Ser-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O AHERARIZBPOMNU-KATARQTJSA-N 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- PYMYPHUHKUWMLA-VPENINKCSA-N aldehydo-D-xylose Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-VPENINKCSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000007073 chemical hydrolysis Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000005782 double-strand break Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 229940054441 o-phthalaldehyde Drugs 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000009962 secretion pathway Effects 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/75—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses food safety bacillus subtilis and application thereof in producing chitobiose deacetylase, and belongs to the technical field of biomolecule modification and genetic engineering. According to the invention, the signal peptide of the expression vector pP43NMKmut-C4-yncM-Dac of the chitobiose deacetylase Dac is screened and optimized, so that the secretion efficiency of the chitobiose deacetylase Dac is improved, the enzyme activity is improved, and a food safety engineering strain capable of stably and efficiently expressing the chitobiose deacetylase Dac is constructed. Compared with the prior art, the extracellular enzyme activity of the chitobiose deacetylase is greatly improved. The conversion method is simple and easy to implement, mild in condition, efficient and environment-friendly, and high in product yield. The method is favorable for solving the problems of serious pollution, low yield and the like in the traditional synthesis method, is easy to control and is favorable for popularization and application.
Description
Technical Field
The invention relates to food safety bacillus subtilis and application thereof in producing chitobiose deacetylase, belonging to the technical field of biomolecule modification and genetic engineering.
Background
Chitosan deacetylase Dac belongs to a carbohydrate esterase and still has a high catalytic activity for acetylglucosamine monomers, and it is characterized in that a substrate which first acts in the metabolic pathway is chitooligosaccharide GlcNAcn or chitobiose GlcNAc2, the lower acetyl group is hydrolyzed from the reducing end of GlcNAcn or GlcNAc2 to produce GlcNAc-GlcN acetylated at the non-reducing end portion, and then GlcNAc-GlcN is hydrolyzed to N-acetylglucosamine GlcNAc and glucosamine GlcN by hydrolysis of exo-glucosaminidase GlmA, and thereafter, chitobiose deacetylase Dac acts again on the produced N-acetylglucosamine GlcNAc monomer to hydrolyze it to glucosamine GlcN.
Compared with most of deacetylases which exist on the market and have catalytic activity on acetylglucosamine in an oligomer or polymer form, the chitobiose deacetylase Dac derived from Thermus thermophilus Pyrococcus horikoshii can perform a single-enzyme catalytic reaction by using N-acetylglucosamine GlcNAc as a substrate, and realizes the one-step efficient production of glucosamine GlcN.
Glucosamine GlcN is an important functional monosaccharide that plays an irreplaceable role in the growth process of organisms. Glucosamine GlcN has been classified as a pharmaceutical agent in many countries as an essential component constituting mucosal secretions, connective tissues, skin, tendons, ligaments, cartilage, and the like. The glucosamine GlcN has good effect in treating the cartilage arthritis and also has certain inhibition effect on the growth of liver cancer cells.
Currently, GlcN glucosamine is classified in the pharmaceutical industry in many countries and is produced by the hydrolysis of chitin and the fermentation of microorganisms. The chitin hydrolysis method is usually used for removing acetyl by strong acid pyrolysis, so that a large amount of environmental pollutants are easily generated, the raw materials are limited by regions and seasons, and the removal degree of acetyl in the obtained product is inconsistent, so that the uniformity of the product is poor. Although the microbial fermentation method overcomes the serious pollution caused by a chemical hydrolysis method, the high-concentration accumulation of the GlcN of the glucosamine in the fermentation liquor is difficult to realize. Because of the wide market for GlcN, it is imperative to find a more efficient and safer GlcN glucosamine production process.
The bacillus subtilis is a typical model industrial microorganism and has the advantages of clear genetic background, mature gene editing and the like. With the continued disclosure of the genetic regulatory mechanisms of Bacillus subtilis, Bacillus subtilis as a "cell factory" for the expression of heterologous proteins has been shown to contain on its genome many nonessential genes that are detrimental to growth and heterologous enzyme expression, such as: at present, genes such as prophage, thallus autolysis, spore formation, heterologous enzyme transcription negative regulation factor and the like are deleted, a regulation metabolic network in a cell is reasonably designed and simplified by means of deleting the genome of the prophage, the production efficiency of a host on the heterologous enzyme is improved while the cell is reduced, and the prophage becomes an ideal chassis cell.
For example, the invention is described in Chinese patent with publication No. CN109777761B, and discloses an engineering bacterium for secretory expression of chitobiose deacetylase Dac and a construction method thereof, wherein the chitobiose deacetylase Dac and the yncM signal peptide are expressed in a fusion manner, a 5' end untranslated region mutant is obtained, and the extracellular enzyme activity is 1548.7U/ml at most after fermentation for 60 hours.
However, the current chitobiose deacetylase Dac has low enzyme activity, and the current engineering bacteria of chitobiose deacetylase Dac still have difficulty in meeting the minimum enzyme activity requirement for industrially preparing glucosamine GlcN by an enzyme method, and the yield and conversion rate of the glucosamine GlcN in the conversion process are low, so that the yield of the glucosamine GlcN needs to be further improved.
Disclosure of Invention
In order to solve the problems of low yield, low activity, unstable passage of engineering strains, limited growth and the like of the chitobiose deacetylase Dac in the prior art, the invention aims to improve the secretion efficiency of the chitobiose deacetylase Dac by screening and optimizing signal peptides; aiming at the optimization and improvement of target protein in a bacillus subtilis expression system, modular modification and assembly are mostly carried out from the aspects of transcription, translation, folding, transportation, strain modification and the like, wherein the transportation of the protein and a signal peptide are in an inseparable relation, and because the knowledge of a secretion mechanism is limited, the accurate estimation of the optimal signal peptide of the protein is difficult, and the application of the signal peptide is still in an exploration stage at present. Although researchers developed predictive tools that aid in the selection of signal peptides, the predicted values and the actual amount of protein secreted appear not to be linear.
The invention selects and optimizes signal peptide, optimizes the underpan cell: bacillus subtilis 168 is used as an original strain, a CRISPR/Cpf1 traceless editing system is introduced to carry out nonsense mutation on extracellular proteases NprE, AprE, NprB, Bpr, Mpr and Epr 6 in the chassis cells, simultaneously, non-essential genes comA and oppA genes for the growth of the chassis cells are knocked out, the output of glucosamine GlcN is further improved by improving biomass, and the enzyme activity of chitobiose deacetylase is improved.
The invention provides a recombinant bacillus subtilis, which takes P43NMK as a carrier, fuses and expresses chitobiose deacetylase and NprB signal peptide, introduces a DNA fragment shown in SEQ ID NO.3 into a 5' untranslated region of the chitobiose deacetylase gene, and the introduction site is positioned after 8 bases behind a +1 transcription initiation site of a promoter P43; the C4 gene with the nucleotide sequence shown in SEQ ID NO.4 is inserted into the 5' end of the NprB signal peptide in the recombinant plasmid.
In one embodiment of the invention, the recombinant bacillus subtilis uses pP43NMKmut-C4-NprB-Dac as a vector, the vector is based on pP43NMKmut-C4-yncM-Dac, and NprB signal peptide is used for replacing yncM signal peptide, and the pP43NMKmut-C4-yncM-Dac vector is disclosed in the paper of 'research on cloning expression of chitobiose deacetylase and biotransformation synthesis of glucosamine, Jiangnan university'.
In one embodiment of the present invention, the NprB signal peptide has an amino acid sequence shown in SEQ ID No.1 and a nucleotide sequence shown in SEQ ID No. 6.
In one embodiment of the present invention, the NprB signal peptide has an amino acid sequence as set forth in SEQ ID No.2 (i.e., NprB optimized for NprB signal peptide)5Signal peptide) with the nucleotide sequence shown in SEQ ID NO. 7.
In one embodiment of the present invention, the chitobiose deacetylase is derived from archaea thermophila, and the gene sequence encoding the chitobiose deacetylase is shown in SEQ ID No. 5.
In one embodiment of the invention, the RBS sequence GTAAGAGAGGAATGTACAC on the p43NMK vector is mutated to GGAAGGGAGGAATAGAGAC.
In one embodiment of the invention, the recombinant Bacillus subtilis is a Bacillus subtilis WB600 host.
In one embodiment of the present invention, the host cell of the recombinant bacillus subtilis is: taking Bacillus subtilis 168 as an initial strain, and knocking out NprE, AprE, NprB, Bpr, Mpr and Epr 6 extracellular proteases and comA and oppA genes on a Bacillus subtilis 168 genome.
In one embodiment of the present invention, the accession numbers of NprE, AprE, NprB, Bpr, Mpr, and Epr genes at NCBI are: 935981, 939313, 936384, 939695, 938430, 937332; the accession numbers of the comA and oppA genes at NCBI are respectively as follows: 937179, 936398.
The invention also provides a method for preparing the chitobiose deacetylase, and the method is prepared by fermenting the recombinant bacillus subtilis.
In one embodiment of the invention, the seed solution of the recombinant bacillus subtilis is inoculated into a TB fermentation medium in an inoculation amount of 2-6% (v/v), and the culture conditions are as follows: culturing at 30-40 deg.C and 160-260rpm for 45-85 h.
The invention also provides a method for constructing the recombinant bacillus subtilis, which comprises the following steps:
(1) preparing a recombinant vector, wherein the recombinant vector is prepared by replacing a yncM signal peptide with an NprB signal peptide on the basis of pP43 NMKmut-C4-yncM-Dac; obtaining a recombinant expression vector pP43 NMKmut-C4-NprB-Dac; the amino acid sequence of the NprB signal peptide is shown as SEQ ID NO.1, or the amino acid sequence of the NprB signal peptide is shown as SEQ ID NO.2
(2) And (2) transferring the recombinant vector prepared in the step (1) into bacillus subtilis to obtain the recombinant bacillus subtilis.
In one embodiment of the invention, the RBS sequence GTAAGAGAGGAATGTACAC of the recombinant vector pP43NMKmut-C4-NprB-Dac is mutated to GGAAGGGAGGAATAGAGAC.
In one embodiment of the present invention, the recombinant bacillus subtilis uses bacillus subtilis WB600 as a host.
In one embodiment of the present invention, the host cell of the recombinant bacillus subtilis is: bacillus subtilis 168 is taken as an initial strain, and NprE, AprE, NprB, Bpr, Mpr and Epr 6 extracellular proteases and comA and oppA genes are knocked out.
The invention also provides a method for preparing glucosamine, which adopts the recombinant bacillus subtilis or the chitobiose deacetylase prepared by the method as a catalyst and N-acetylglucosamine as a substrate.
In one embodiment of the invention, the substrate has a final concentration of 65 to 185 g/L.
In one embodiment of the present invention, the reaction conditions of the process are: reacting for 2-62min at 30-60 ℃.
In one embodiment of the invention, the method comprises the steps of using the fermentation supernatant of the recombinant bacillus subtilis as a catalyst, inoculating a seed culture solution into a fermentation culture medium according to the inoculation amount of 2-6% (v/v), culturing at 37-40 ℃ for 45-85h, and centrifuging at 10000-.
In one embodiment of the present invention, the seed culture solution is recombinant Bacillus subtilis cultured at 30-40 ℃ until OD600 is 3.0-6.0.
In one embodiment of the invention, the fermentation medium comprises: peptone 12g/L, yeast extract 24g/L, glycerin 4mL, KH2PO42.31g/L and K2HPO412.54 g/L。
The invention also provides application of the recombinant bacillus subtilis in preparation of medicines or dietary supplements.
The invention also provides application of the recombinant bacillus subtilis in preparation of glucosamine or products containing glucosamine.
The invention also provides a method for improving the secretion efficiency of the chitobiose deacetylase Dac.
The invention also provides a method for improving the expression level of the chitobiose deacetylase Dac.
The invention also provides a method for improving the growth rate of the engineering strain of the chitobiose deacetylase Dac.
The invention also provides Bacillus subtilis ZR6AA/pP43NMKmut-C4-NprB5-R2-Dac construction method and application of engineering strain.
Advantageous effects
(1) According to the invention, the signal peptide of the expression vector pP43NMKmut-C4-yncM-Dac of the chitobiose deacetylase Dac is screened and optimized, and the chassis cells are optimized, so that the secretion efficiency of the chitobiose deacetylase Dac is improved, the enzyme activity is improved, and the food safety engineering strain capable of stably and efficiently expressing the chitobiose deacetylase Dac is constructed. Compared with the prior art, the extracellular enzyme activity of the chitobiose deacetylase is greatly improved. The conversion method is simple and easy to implement, mild in condition, efficient and environment-friendly, and high in product yield. The method is favorable for solving the problems of serious pollution, low yield and the like in the traditional synthesis method, is easy to control and is favorable for popularization and application.
(2) The invention further modifies the recombinant strain of Bacillus subtilis WB600/pP43NMKmut-C4-yncM-Dac to replace the original signal peptide, the constructed recombinant strain of Bacillus subtilis WB600/p43NMKmut-C4-NprB-Dac is fermented for 60h, the extracellular enzyme activity reaches up to 3168U/mL, and the constructed recombinant strain of Bacillus subtilis WB600/p43NMKmut-C4-NprB is optimized to the signal peptide5The extracellular enzyme activity of the recombinant strain Dac can reach 3682.2U/mL after fermentation for 60 h.
(3) The invention is characterized in that Bacillus subtilis WB600/p43NMKmut-C4-NprB5Dac recombinant strain, and the recombinant vector pP43NMKmut-C4-NprB is further modified5The RBS sequence GTAAGAGAGGAATGTACAC on the-Dac is mutated into GGAAGGGAGGAATAGAGAC to obtain Bacillus subtilis WB600/p43NMKmut-C4-NprB5-R2Dac recombinant strain, which ferments for 60h and has extracellular enzyme activity reaching 4012.3U/mL.
(4) The recombinant strain Bacillus subtilis ZR6AA/p43NMKmut-C4-NprB is constructed by modifying host cells, taking Bacillus subtilis 168 as an initial strain, carrying out nonsense mutation on extracellular proteases of NprE, AprE, NprB, Bpr, Mpr and Epr 6, knocking out comA and oppA genes influencing the growth of the strain, improving biomass, slowing down the cracking death of the strain at the later stage of fermentation and obtaining the recombinant strain Bacillus subtilis ZR6AA/p43NMKmut-C4-NprB5-R2Dac, the extracellular enzyme activity of the strain can reach 4774.2U/mL after 60h fermentation, and is improved by 2.08 times compared with the original strain.
Drawings
FIG. 1: the present invention is chitobiose deacetylase Dac catalyzing the reaction process.
FIG. 2: the construction of different signal peptide strains in the invention is shown schematically.
FIG. 3: in the embodiment 1 of the invention, different signal peptides guide the secretion of the chitobiose deacetylase Dac to the outside of the cell, and the comparison of the activity of the extracellular enzyme and the yield of glucosamine is carried out.
FIG. 4: the functional region of the signal peptide NprB in example 2 of the present invention was divided.
FIG. 5: different mutants of signal peptide NprB in embodiment 2 of the invention guide secretion of chitobiose deacetylase Dac to the outside of cells, and the comparison of the activity of the extracellular enzyme and the yield of glucosamine is carried out.
FIG. 6: the effect of RBS sequences of different translational strengths on the extracellular enzymatic activity of chitobiose deacetylase Dac and the production of glucosamine in example 3 of the present invention.
FIG. 7: bacillus subtilis WB600/p43NMKmut-C4-NprB constructed in embodiment 3 of the invention5-R2Dac SDS-PAGE analysis of fermentation supernatants from Bacillus subtilis WB600/p43NMK producing no-chitobiose deacetylase Dac and from Bacillus subtilis WB600/p43NMKmut-C4-YncM-Dac producing originally chitobiose Dac; in lane 1, recombinant Bacillus subtilis WB600/p43NMKmut-C4-NprB5-R2-Dac; lane 2, fermentation supernatant of Bacillus subtilis WB600/p43 NMKmut-C4-YncM-Dac; lane 3: fermentation supernatant of Bacillus subtilis WB600/p43 NMK.
FIG. 8: in the embodiment 5 of the invention, when the constructed novel underpan cell Bacillus subtilis ZR6AA is taken as an expression host, the extracellular enzyme activity of the chitobiose deacetylase Dac is compared with that of the Bacillus subtilis WB600 taken as the expression host.
FIG. 9: in the embodiment 5 of the invention, when the constructed novel underpan cell Bacillus subtilis ZR6AA is taken as an expression host, the growth condition of the cell is compared with that when Bacillus subtilis WB600 is taken as the expression host.
Detailed Description
The present invention will be explained in detail below with reference to examples and the accompanying drawings.
The vector pP43NMKmut-C4-yncM-Dac, referred to in the following examples, was disclosed in the "study on the cloning expression and biotransformation of chitobiose deacetylase to glucosamine, Jiangzhu, university of Jiangnan".
The detection methods referred to in the following examples:
the enzymatic activity detection method of the chitobiose deacetylase comprises the following steps:
the enzyme activity of the crude enzyme liquid is detected by an o-phthalaldehyde color development method, and the specific mode is as follows:
taking 1mL of fermentation liquid fermented for 60h, and separating at 1200rpm, 4 deg.C for 2minAnd (4) taking supernatant as crude enzyme liquid, and taking a substrate as 100g/L N-acetylglucosamine GlcNAc solution. 100 mu L of each of the crude enzyme solution to be detected and the substrate are respectively loaded in a 1.5mL EP tube and preheated for 5min at 40 ℃. Adding preheated 100 mu L of crude enzyme solution into 100 mu L of substrate, carrying out shake reaction at 40 ℃ for 2min, accurately timing, and adding 0.5mol/L HCl terminator to terminate the reaction. Centrifuging at 1200rpm for 2min, collecting supernatant 50 μ L in 950 μ L PB1Diluting by 20 times, mixing uniformly, adding 5 μ L into 100 μ L1 × OPA detection reagent, and shaking for 2 min. The absorbance at 330nm was measured using a microplate reader. And taking the inactivated enzyme solution as a reaction blank control.
And (3) drawing a standard curve of the glucosamine hydrochloride, accurately weighing a standard substance (accurate to 0.0001g) to prepare 0.5g/L, 1g/L, 2g/L, 3g/L, 4g/L and 5g/L glucosamine hydrochloride solution, adding 5 mu L glucosamine hydrochloride solution into 100 mu L OPA detection reagent, shaking for 1min, and preserving the temperature at 30 ℃ for 2 min. And detecting the light absorption value at 330nm by using a microplate reader, and drawing a standard curve.
The enzyme activity calculation formula is as follows:
in the formula: x: crude enzyme liquid enzyme activity (U/mL); a: the volume of the crude enzyme solution is 0.1 (mL); b: substrate solution volume 0.1 (mL); m: the dilution factor of the sample is 1.5 after the terminator is added; c: GlcN concentration (g/L) of the reaction solution; d: GlcN concentration (g/L) of the blank liquid. T: reaction time 2 (min); 60: 1h is 60 min; 215.6: molar mass of glucosamine hydrochloride (g/mol) of the standard sample; 0.1: number of volumes of substrate solution (mL) x: the dilution ratio of the enzyme solution is 20.
The detection reagents involved are as follows:
substrate N-acetylglucosamine solution (100 g/L): 5g N GlcNAc of acetylglucosamine is soluble in PB1In (1), with PB1The volume is up to 50 mL.
PB1Sodium phosphate buffer (200mmol/L, pH 8.0): NaH with the concentration of 200mmol/L is prepared2PO4Solution and Na2HPO4And (3) solution. 18mL NaH2PO4Solution with 390mL Na2HPO4The solution was mixed well. The pH was measured with a pH meter to determine pH 8.0 and stored at room temperature.
PB2Sodium carbonate buffer (100mmol/L, pH 10.5): NaCO with the preparation concentration of 100mmol/L3Solution and NaHCO3And (3) solution. 18mL NaH2PO4Solution with 390mL Na2HPO4The solution was mixed well. The pH was measured with a pH meter to determine pH 10.5 and stored at room temperature.
DTT dithiothreitol (2 mol/L): 308.5mg of dithiothreitol is weighed into 1mL of dd H2O, mixed evenly, sealed and stored at low temperature.
10 × OPA detection reagent: 500mg of ortho-phthalaldehyde OPA 100mL PB2Mixing, sealing, storing at low temperature and in dark place.
1 × OPA detection reagent: 3mL 10 XOPA, 300. mu.L absolute ethanol, 15. mu.L LDTT, plus PB2The volume is determined to be 30mL, and after being mixed evenly, the mixture is sealed and stored in dark at low temperature. It is prepared as before use.
HCl terminator (0.5 mol/L): 1800 μ L of hydrochloric acid was taken in 40mL dd H2O.
Definition of enzymatic Activity of Chitosan deacetylase: the amount of enzyme required for 1h to convert 1. mu. mol of substrate N-acetylglucosamine GlcNAc to 1. mu. mol of product glucosamine GlcN at 40 ℃ is referred to as one unit of enzyme activity, i.e., 1U ═ 1. mu. mol/h.
The media involved in the following examples are as follows:
LB liquid Medium (g/L): sterilizing yeast powder 5, peptone 10 and NaCl 10 at 121 ℃ for 15 min.
LB solid Medium (g/L): 5 parts of yeast powder, 10 parts of peptone, 10 parts of NaCl and 20 parts of agar powder, and sterilizing for 15min at 121 ℃.
TB fermentation Medium (g/L): yeast powder 24, peptone 12, glycerol 4, KH2PO4 2.31，K2HPO412.54, sterilizing at 115 deg.C for 20 min.
Example 1: the construction of the recombinant bacillus subtilis, the expression of the chitobiose deacetylase Dac and the screening of the signal peptide comprise the following steps:
(1) selecting 12 Bacillus subtilis endogenous signal peptides in the same secretion pathway, wherein specific signal peptides and sequences thereof are shown in Table 1:
table 1: different signal peptides and sequences
(2) Through a Simple cloning method, as shown in figure 2, a recombinant plasmid pP43NMKmut-C4-yncM-Dac (a specific construction method is disclosed in the paper of 'research on cloning expression and biotransformation of chitobiose deacetylase to synthesize glucosamine, Jiangzhu, Jiangnan university') is used as a template, a primer sequence is shown in table 2, PCR amplification is carried out, Escherichia coli DH5 alpha is transformed after nucleic acid electrophoresis gel verification, and then the plasmid is extracted from a transformant with a correct sequencing result, and the transformant is transferred into an expression host Bacillus subtilis WB 600.
Table 2: primer sequences for different signal peptides
(3) Transformants carrying different signal peptides were picked using an inoculating loop and seed cultured in 50mL centrifuge tubes. Each tube contains 5mL LB liquid culture medium added with kanamycin antibiotic (10mg/mL), the addition volume of the antibiotic is 1 per mill of the volume of the liquid culture medium, and the seed liquid is obtained after the culture is carried out for 12h at 37 ℃ and 220 rpm; transferring the prepared seed solution to 96mL TB liquid culture medium added with kanamycin antibiotic (10mg/mL) for fermentation culture in a 500mL conical flask in an inoculation amount of 4% (v/v), culturing at 37 ℃ and 220rpm for 60h to prepare fermentation liquid, and centrifuging the fermentation liquid at 4 ℃ and 12000rpm for 2min to obtain fermentation supernatant, namely crude enzyme solution.
(4) The crude enzyme solution prepared in step (3) was subjected to enzyme activity detection, and the results are shown in table 3 and fig. 3.
(5) Taking 1mL of fermentation supernatant as a catalyst, taking N-acetylglucosamine with the final concentration of 100g/L as a substrate, reacting at 40 ℃ for 2min to prepare glucosamine hydrochloride, and detecting the content of the glucosamine hydrochloride as shown in table 3 and figure 3, wherein Control represents the experimental result that the signal peptide is yncM (the specific catalytic reaction principle is shown in figure 1).
Table 3: enzyme activity of chitobiose deacetylase prepared by fermentation of recombinant bacteria containing different signal peptides and yield of glucosamine (glucosamine for short) prepared by recombinant strains containing different signal peptides
The signal peptide NprB is the optimal signal peptide obtained by screening through conical flask fermentation verification, as shown in figure 3, the enzyme activity peak value of the supernatant reaches 3168U/mL after 60 hours of fermentation, the glucosamine yield reaches 158.4mol/L, and the maximum level is the highest level of all recombinant strains.
Example 2: optimization of dominant signal peptide of chitobiose deacetylase Dac
Optimizing signal peptide NprB, mutating methionine at 1 st position of signal peptide with amino acid sequence shown as SEQ ID NO.1 into lysine to obtain mutant M1K named as NprB1；
The methionine at the 1 st site of the signal peptide with the amino acid sequence shown as SEQ ID NO.1 is mutated into lysine, and the asparagine at the 3 rd site is mutated into lysine to obtain a mutant M1K-N3K which is named as NprB2；
Mutating methionine at 1 st position of signal peptide with amino acid sequence shown as SEQ ID NO.1 to lysine, mutating asparagine at 3 rd position to lysine, and mutating threonine at 5 th position to lysine to obtain mutant M1K-N3K-T5K, named as NprB3；
The methionine at the 1 st site of the signal peptide with the amino acid sequence shown as SEQ ID NO.1 is mutated into lysine, the asparagine at the 3 rd site is mutated into lysine, and the threonine at the 5 th site is mutated into lysineThe acid mutation is lysine, the leucine mutation at the 9 th position is glutamine, and the mutant M1K-N3K-T5K-L9Q which is named as NprB is obtained4；
Mutating methionine at 1 st position of signal peptide with amino acid sequence shown as SEQ ID NO.1 into lysine, mutating asparagine at 3 rd position into lysine, mutating threonine at 5 th position into lysine, mutating leucine at 9 th position into glutamine, mutating leucine at 11 th position into aspartic acid to obtain mutant M1K-N3K-T5K-L9Q-L11D, named as NprB5；
The sequences of the primers involved are shown in Table 4:
table 4: primer sequences for different mutants
Respectively constructing 5 mutants of NprB by taking pP43NMKmut-C4-NprB-Dac as a template and adopting the primer sequences through PCR amplification1、NprB2、NprB3、NprB4、NprB5The recombinant vector pP43NMKmut-C4-NprB1-Dac，pP43NMKmut-C4-NprB2-Dac，pP43NMKmut-C4-NprB3-Dac，pP43NMKmut-C4-NprB4-Dac，pP43NMKmut-C4-NprB5-Dac。
Respectively constructing recombinant bacteria by using the recombinant vectors and Bacillus subtilis WB600 as expression hosts according to the method of the embodiment 1, performing fermentation culture, performing enzyme activity detection, and detecting the content of the prepared glucosamine.
The results were confirmed by Erlenmeyer flask fermentation, as shown in FIG. 5 and Table 5, where Control represents experimental data for recombinant bacteria containing the signal peptide NprB before mutation.
Table 5: enzyme activity of chitobiose deacetylase prepared by fermentation of recombinant strains containing different signal peptide mutants and yield of glucosamine (glucosamine for short) prepared by recombinant strains containing different signal peptide mutants
As a result, it was found that the mutant M1K-N3K-T5K-L9Q-L11D, i.e., NprB, contained the signal peptide5The peak value of the enzyme activity of the supernatant after 60 hours of fermentation of the recombinant strain reaches 3682.2U/mL, and the yield of glucosamine is up to 184.11 mol/L.
Example 3: RBS sequence optimization
The RBS on the recombinant vector is optimized, and the specific steps are as follows:
pP43NMKmut-C4-NprB prepared as described in example 25-R0Dac (for descriptive convenience, the non-optimized pre-recombinant vector pP43NMKmut-C4-NprB5-Dac, p43NMKmut-C4-NprB5-R0Dac) as a template, and carrying out PCR amplification by using primers shown in Table 6 to obtain a recombinant vector pP43NMKmut-C4-NprB5-R1-Dac，pP43NMKmut-C4-NprB5-R2-Dac，pP43NMKmut-C4-NprB5-R3-Dac，pP43NMKmut-C4-NprB5-R4-Dac，pP43NMKmut-C4-NprB5-R5-Dac。
TABLE 6 primer sequences
The recombinant vectors are respectively constructed by taking Bacillus subtilis WB600 as an expression host according to the method of the embodiment 1, fermentation culture and enzyme activity detection are carried out, and the results are shown in FIG. 6 and Table 7, wherein Control represents experimental data of the recombinant bacteria containing the original RBS sequence.
Table 7: enzyme activity of chitobiose deacetylase prepared by fermentation of recombinant bacteria containing different RBS sequences and yield of glucosamine (glucosamine for short) prepared by recombinant strains containing different RBS sequences
As shown in FIG. 6, the recombinant strain Bacillus subtilis WB600/p43NMKmut-C4-NprB5-R2The extracellular enzyme activity is the highest after 60h of fermentation of Dac, and is up to 4012.3U/mL, and the glucosamine yield is up to 200.615 mol/L.
The obtained strain Bacillus subtilis WB600/p43NMKmut-C4-NprB5-R2FIG. 7 shows SDS-PAGE analysis of Dac and Bacillus subtilis WB600/p43NMKmut-C4-YncM-Dac which produced chitobiose deacetylase Dac and Bacillus subtilis WB600/p43NMK which produced no chitobiose deacetylase Dac, wherein 1, 2, and 3 lanes correspond to Bacillus subtilis WB600/p43NMKmut-C4-NprB5-R2Dac, Bacillus subtilis WB600/p43NMKmut-C4-YncM-Dac and Bacillus subtilis WB600/p43NMK, and a significant target protein band at 31.8kDa can be seen from FIG. 7, which proves that the chitobiose deacetylase Dac is expressed.
Example 4: construction of Bacillus subtilis ZR6AA as Bacillus subtilis underpan cell
The method comprises the following specific steps:
CRISPR editing is achieved by the endonuclease activity of Cas protein Cpf1, and Cpf1 protein will cleave at specific sites of genome under the mediation of guide rna (crrna), resulting in double-strand break.
1. construction of crRNA vectors
The CRISPR-DT website is designed on line by means of the crRNA to design the crRNA with high specificity so as to reduce the off-target phenomenon. The primers listed in Table 8 were used to amplify crRNA fragments of comA and oppA genes to be knocked out, and then the amplified crRNA fragments were assembled with vector pcrF17NM (the construction method of vector pcrF17NM is disclosed in CAMERS-B: CRISPR/Cpf1assisted multiple-genes editing and regulation system for Bacillus subtilis, Yaokang Wu, Jiangnan University), and transformed into Escherichia coli DH 5. alpha. after sequencing verification, it was shown that 4 crRNA vectors were successfully constructed.
Table 8: primer sequences
2. Homologous repair template vector construction
And (3) amplifying upstream and downstream homologous arms (sequences are shown in table 9) of the comA and oppA genes to be knocked out, connecting the upstream and downstream homologous arms with the corresponding crRNA vector constructed in the step (1) by means of Biyun one-step cloning ligase, constructing a homologous repair template vector for knocking out the comA and oppA genes, converting the homologous repair template vector into Escherichia coli DH5 alpha, and carrying out sequencing verification.
Table 9: upstream and downstream homology arms for comA and oppA
3. Cas protein Cpf1 competent cell preparation
Plasmid pHT-XCR6 (the construction method of plasmid pHT-XCR6 discloses CAMERS-B: CRISPR/Cpf1 associated multiple-genes editing and formatting system for Bacillus subtilis, Yaokang Wu, Jiangnan University paper) is a Cas protein Cpf1 expression vector, wherein Cpf1 is induced and controlled by xylose.
The plasmid pHT-XCR6 is transformed into BSZR600 (the construction method of BSZR600 is disclosed in CAMERS-B: CRISPR/Cpf1 associated multiple-genes editing and formatting system for Bacillus subtilis, Yaokang Wu, Jiangnan University, is a Bacillus subtilis chassis cell which is constructed by knocking out NprE, AprE, NprB, Bpr, Mpr and Epr 6 extracellular proteases by taking Bacillus subtilis 168 as a starting strain, and then the transformant is made to be competent positively, which comprises the following steps: picking a single colony of the inoculating loop in 2mL of liquid LB culture medium containing chloramphenicol (5mg/mL) resistance, wherein the addition volume of the antibiotic is 1 per mill of the volume of the liquid culture medium, and culturing at 37 ℃ and 220rpm for 12 h; measuring OD600Diluted to OD with liquid medium LB and xylose6001.0, controlling the final concentration of xylose at 3%, culturing at 37 ℃ and 220rpm for 2 h; the strain was in a competent state at this time, and glycerol was added to the strain at a final concentration of 10% and stored at-80 ℃ for further use.
4. Homologous repair template plasmid transformation
Adding the homologous repair template vector in the step 2 into the Cas protein Cpf1 competent cell prepared in the step 3, and culturing at 37 ℃ and 220rpm for 2 h; and centrifugally resuspending the bacterial liquid in 500 mu L of LB liquid culture medium containing chloramphenicol, kanamycin and 3% xylose, culturing at 37 ℃ and 220rpm for 12h, centrifugally concentrating to 150 mu L of LB solid culture medium coated with chloramphenicol, kanamycin and 3% xylose, and carrying out colony PCR (polymerase chain reaction) verification to determine whether the gene editing is finished after single bacteria grow out from the LB solid culture medium.
5. Elimination of plasmids
And (3) selecting the positive bacterial colony prepared in the step (4) by using an inoculating loop to a non-resistant LB liquid culture medium added with 0.005% -0.006% lauryl sodium sulfate, culturing at 37 ℃ and 220rpm for 6h, streaking the non-resistant LB solid culture medium, culturing in a 37 ℃ culture box for 12h, selecting a single bacterial colony to an LB solid culture medium containing chloramphenicol and kanamycin, and performing plasmid elimination verification. Successfully eliminating the plasmid to obtain a new Bacillus subtilis ZR6AA of the Bacillus subtilis chassis cell; the Bacillus subtilis ZR6AA strain takes Bacillus subtilis 168 as an initial strain, and knocks out NprE, AprE, NprB, Bpr, Mpr and Epr 6 extracellular proteases, and knocks out comA and oppA genes.
Example 5: chassis cell modification strain fermentation verification
The method comprises the following specific steps:
1. preparation of Chassis cell modified strain competence
The novel Bacillus subtilis ZR6AA obtained in example 4 was made competent according to the Cas protein Cpf1 competent cell preparation method in step 3 of example 4.
2. Chassis cell modification strain fermentation verification
The recombinant vector p43NMKmut-C4-NprB prepared in example 3 was used5-R2Dac, transformed into Bacillus subtilis ZR6AA to obtain Bacillus subtilis ZR6AA/p43NMKmut-C4-NprB5-R2-Dac recombinant strain;
according to the method of example 1, the prepared recombinant strain is fermented and the enzyme activity is detected, and the extracellular enzyme activity can reach 4774.2U/mL at 60h of fermentation, compared with 4774.2U/mLThe original strain Bacillus subtilis WB600/pP43NMKmut-C4-yncM-Dac (blank control 1 in figure 8, the enzyme activity is 1548.7U/mL) is improved by 2.08 times, and compared with the strain Bacillus subtilis WB600/p43NMKmut-C4-NprB obtained in the embodiment 35-R2-Dac (blank Control 2 in FIG. 8, enzyme activity 4012.3U/mL) was improved by 18.98%, and the results are shown in FIG. 8 or Table 10, wherein Control-1 indicates: bacillus subtilis WB600/pP43NMKmut-C4-yncM-Dac recombinant bacteria; control-2 denotes: bacillus subtilis WB600/p43NMKmut-C4-NprB5-R2-Dac recombinant bacteria; Δ comA Δ oppA denotes: bacillus subtilis ZR6AA/p43NMKmut-C4-NprB5-R2Dac recombinant bacterium.
Table 10: enzyme activity of chitobiose deacetylase prepared by fermentation of different recombinant bacteria and yield of glucosamine (glucosamine for short) prepared by chitobiose deacetylase
The growth of the recombinant strain was also improved upon reconstitution of the underpan cells, as shown in FIG. 9, where control in FIG. 9 represents Bacillus subtilis WB600/p43NMKmut-C4-NprB5-R2-Dac recombinant bacteria; Δ comA Δ oppA denotes: bacillus subtilis ZR6AA/p43NMKmut-C4-NprB5-R2Dac recombinant bacterium.
Although the present invention has been described with reference to the preferred embodiments, it should be understood that various changes and modifications can be made therein by those skilled in the art without departing from the spirit and scope of the invention as defined in the appended claims.
SEQUENCE LISTING
<110> university of south of the Yangtze river
<120> food safety-grade bacillus subtilis and application thereof in production of chitobiose deacetylase
<130> BAA210594A
<160> 7
<170> PatentIn version 3.3
<210> 1
<211> 28
<212> PRT
<213> Artificial sequence
<400> 1
Met Arg Asn Leu Thr Lys Thr Ser Leu Leu Leu Ala Gly Leu Cys Thr
1 5 10 15
Ala Ala Gln Met Val Phe Val Thr His Ala Ser Ala
20 25
<210> 2
<211> 28
<212> PRT
<213> Artificial sequence
<400> 2
Lys Arg Lys Leu Lys Lys Thr Ser Gln Leu Asp Ala Gly Leu Cys Thr
1 5 10 15
Ala Ala Gln Met Val Phe Val Thr His Ala Ser Ala
20 25
<210> 3
<211> 73
<212> DNA
<213> Artificial sequence
<400> 3
ggtaccatta taggtaagag aggaatgtac acatggtcgt caacatgttc gaggacatcg 60
acacgttcga gga 73
<210> 4
<211> 45
<212> DNA
<213> Artificial sequence
<400> 4
atgaaaaaaa tcacaacaaa cgaacaattt aatgaactga ttcaa 45
<210> 5
<211> 819
<212> DNA
<213> Artificial sequence
<400> 5
atggtcgtca acatgttcga ggacatcgac acgttcgagg aagcgtttaa caagctgctg 60
cgcgaagtcc tggaatttga tctgcaaaat ccgttcaaag acgcgaagaa agtcctttgc 120
atcgaaccgc atccggacga ttgcgttatt ggaatgggcg gcacaatcaa aaaactgagc 180
gatatgggcg tcgaagtcat ctacgtttgc atgacagacg gctatatggg cacaacagac 240
gaaagcctgt caggacacga attagcagca atccgccgca aagaagaaga agaaagcgca 300
cgcctgctgg gcgttaaaaa gatctattgg ctgaactacc gcgatacaga actgccgtat 360
tcacgcgaag tccgcaaaga tctgacgaaa attctgcgca aagaacaacc ggacggagtt 420
tttgcaccag atccttggct tccgtacgaa tcacatccgg atcatagacg cacaggcttt 480
ctggcgattg aatcagttgc gtttagccag ctgccgaatt ttagcaacac ggatctggac 540
attggcctga atccgtataa cagcggaagc tttatcgcgc tgtactacac gcacaaaccg 600
aactacatcg tcgacatcac ggacctgatg gaactgaaac tgaaggcgat tcgcgtccat 660
agaagccagt ttccggacga tatttgggag aaatgggaac cgttcctgag aacaatcgcg 720
atgttctacg gcgaaaaaat cggcgttcgc tacggagaag gctttagaat tatgccgggc 780
ctgttctacc acatcacacc gtttacggac ctgatctga 819
<210> 6
<211> 84
<212> DNA
<213> Artificial sequence
<400> 6
ttgcgcaact tgaccaagac atctctatta ctggccggct tatgcacagc ggcccaaatg 60
gtttttgtaa cacatgcctc agct 84
<210> 7
<211> 84
<212> DNA
<213> Artificial sequence
<400> 7
aaacgcaaat tgaaaaagac atctcagtta gacgccggct tatgcacagc ggcccaaatg 60
gtttttgtaa cacatgcctc agct 84
Claims (10)
1. A recombinant Bacillus subtilis is characterized in that P43NMK is used as a vector, a chitobiose deacetylase and an NprB signal peptide are subjected to fusion expression, a DNA fragment shown in SEQ ID NO.3 is introduced into a 5' untranslated region of a chitobiose deacetylase gene, and the introduction site is positioned 8 bases behind a +1 transcription initiation site of a promoter P43; the C4 gene with the nucleotide sequence shown in SEQ ID NO.4 is inserted into the 5' end of the NprB signal peptide in the recombinant plasmid.
2. The recombinant bacillus subtilis of claim 1, wherein the amino acid sequence of the NprB signal peptide is set forth in SEQ ID No.1 or SEQ ID No.2, and the gene sequence encoding the chitobiose deacetylase is set forth in SEQ ID No. 5.
3. The recombinant Bacillus subtilis of claim 1 or 2 wherein the RBS sequence GTAAGAGAGGAATGTACAC on the p43NMK vector is mutated to GGAAGGGAGGAATAGAGAC.
4. The recombinant Bacillus subtilis according to any one of claims 1 to 3, wherein Bacillus subtilis WB600 is used as the host.
5. The recombinant Bacillus subtilis of any one of claims 1 to 3 wherein the host cell of the recombinant Bacillus subtilis is: taking Bacillus subtilis 168 as an initial strain, and knocking out NprE, AprE, NprB, Bpr, Mpr and Epr 6 extracellular proteases and comA and oppA genes on a Bacillus subtilis 168 genome.
6. A method for preparing chitobiose deacetylase, which is characterized in that the recombinant Bacillus subtilis of any one of claims 1 to 5 is used for fermentation preparation.
7. The method of claim 6, wherein the seed solution of the recombinant Bacillus subtilis is inoculated into the TB fermentation medium in an inoculum size of 2-6% under the following culture conditions: culturing at 30-40 deg.C and 160-260rpm for 45-85 h.
8. A method for preparing glucosamine, which comprises using the recombinant Bacillus subtilis of any one of claims 1 to 5 or the chitobiose deacetylase prepared by the method of claim 6 or 7 as a catalyst, and using N-acetylglucosamine as a substrate to prepare glucosamine.
9. Use of the recombinant bacillus subtilis of any one of claims 1-5 for the preparation of a medicament or dietary supplement.
10. Use of the recombinant Bacillus subtilis of any one of claims 1-5 for the preparation of glucosamine or a glucosamine-containing product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110536143.4A CN113151135A (en) | 2021-05-17 | 2021-05-17 | Food safety-grade bacillus subtilis and application thereof in production of chitobiose deacetylase |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110536143.4A CN113151135A (en) | 2021-05-17 | 2021-05-17 | Food safety-grade bacillus subtilis and application thereof in production of chitobiose deacetylase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113151135A true CN113151135A (en) | 2021-07-23 |
Family
ID=76876389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110536143.4A Pending CN113151135A (en) | 2021-05-17 | 2021-05-17 | Food safety-grade bacillus subtilis and application thereof in production of chitobiose deacetylase |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113151135A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114561386A (en) * | 2022-02-21 | 2022-05-31 | 湖南农业大学 | Gene element with intramolecular chaperone characteristic and application thereof |
| CN114591881A (en) * | 2022-03-17 | 2022-06-07 | 山东润德生物科技有限公司 | Bacillus subtilis secreting chitobiose deacetylase and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109777761A (en) * | 2019-03-14 | 2019-05-21 | 江南大学 | A kind of the engineering bacteria building and its application of secreting, expressing Diacetylchitobiose deacetylase |
| CN112553134A (en) * | 2020-12-30 | 2021-03-26 | 江南大学 | Method for expressing alpha-amylase in bacillus subtilis |
| CN112680434A (en) * | 2021-02-01 | 2021-04-20 | 江南大学 | Method for improving secretory expression of protein glutaminase |
-
2021
- 2021-05-17 CN CN202110536143.4A patent/CN113151135A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109777761A (en) * | 2019-03-14 | 2019-05-21 | 江南大学 | A kind of the engineering bacteria building and its application of secreting, expressing Diacetylchitobiose deacetylase |
| CN112553134A (en) * | 2020-12-30 | 2021-03-26 | 江南大学 | Method for expressing alpha-amylase in bacillus subtilis |
| CN112680434A (en) * | 2021-02-01 | 2021-04-20 | 江南大学 | Method for improving secretory expression of protein glutaminase |
Non-Patent Citations (1)
| Title |
|---|
| 姜竹: "几丁二糖脱乙酰酶的克隆表达与生物转化合成氨基葡萄糖的研究", 《中国优秀博硕士学位论文全文数据库(硕士)基础科学辑》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114561386A (en) * | 2022-02-21 | 2022-05-31 | 湖南农业大学 | Gene element with intramolecular chaperone characteristic and application thereof |
| CN114561386B (en) * | 2022-02-21 | 2024-05-28 | 湖南农业大学 | Gene element with intramolecular chaperone characteristic and application thereof |
| CN114591881A (en) * | 2022-03-17 | 2022-06-07 | 山东润德生物科技有限公司 | Bacillus subtilis secreting chitobiose deacetylase and application thereof |
| CN114591881B (en) * | 2022-03-17 | 2023-07-21 | 山东润德生物科技有限公司 | Bacillus subtilis secreting chitosan deacetylase and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108795916B (en) | Lysine decarboxylase mutant, coding gene thereof, expression and application thereof | |
| CN112877272B (en) | Escherichia coli engineering bacteria of N-acetylglucosamine and fermentation production method | |
| CN109486734B (en) | Genetically engineered bacterium for producing chondroitin and construction method and application thereof | |
| CN113122490B (en) | Double-gene defective engineering bacterium and application thereof in improving yield of N-acetylglucosamine | |
| CN113151135A (en) | Food safety-grade bacillus subtilis and application thereof in production of chitobiose deacetylase | |
| CN114874964B (en) | Construction method and application of recombinant escherichia coli for high yield of 2' -fucosyllactose | |
| CN112301012B (en) | Cyclodextrin glucosyltransferase mutant and construction method thereof | |
| US20230272443A1 (en) | N-Acetylglucosamine-Producing Bacterial Strain As Well As Method Of Construction And Use Thereof | |
| US10233439B2 (en) | Directed modification of glucosamine synthase mutant and application thereof | |
| CN113122527B (en) | Aspartase mutant with improved enzyme activity and changed optimal pH | |
| CN113073074B (en) | Genetically engineered bacterium for efficiently synthesizing riboflavin and application thereof | |
| JP4235262B2 (en) | Production of non-native bacterial exopolysaccharides in recombinant bacterial hosts | |
| CN111411066B (en) | Double-way composite neuraminic acid-producing bacillus subtilis and construction method thereof | |
| CN111394410B (en) | High-catalytic-activity neuraminic acid synthase and application thereof | |
| CN113528495A (en) | Bacillus subtilis for stably expressing chitobiose deacetylase and construction method and application thereof | |
| CN108103049B (en) | Thermophilic L-asparaginase mutant and screening and fermenting method thereof | |
| CN113430127B (en) | Recombinant bacterium for producing L-lactic acid and application thereof | |
| CN115948265A (en) | Kluyveromyces marxianus haploid yeast and construction method and application thereof | |
| CN110872595B (en) | Acid-resistant expression cassette and application thereof in fermentation production of organic acid | |
| CN114107148B (en) | Genetically engineered strain for high-yield hyaluronic acid and application thereof | |
| CN112210544B (en) | Cyclodextrin glucosyltransferase mutant and application thereof | |
| CN115011536B (en) | Engineering bacterium for producing high optical purity D-lactic acid by double anaerobic promoters and preparation method and application thereof | |
| CN114591881B (en) | Bacillus subtilis secreting chitosan deacetylase and application thereof | |
| CN111607548B (en) | Recombinant escherichia coli for producing mannan and application thereof | |
| CN115960856A (en) | Glycosyltransferase fusion enzyme variant and application thereof in AA-2G preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210723 |
|
| RJ01 | Rejection of invention patent application after publication |